down arrow

Cullinan Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2300311063
USD
10.59
0.01 (0.09%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Theravance Biopharma, Inc.
SIGA Technologies, Inc.
Zymeworks, Inc.
Liquidia Corp.
Marinus Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc.
Procaps Group SA
Oculis Holding AG
Icosavax, Inc.
Cullinan Therapeutics, Inc.
Biomea Fusion, Inc.
Why is Cullinan Therapeutics, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is Cullinan Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Cullinan Therapeutics, Inc.
-14.87%
-0.68
71.98%
S&P 500
12.66%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-221.77%
EBIT to Interest (avg)
-139.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.55
Sales to Capital Employed (avg)
0.04
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
2.63%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.97
EV to EBIT
-1.12
EV to EBITDA
-1.12
EV to Capital Employed
0.94
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-83.79%
ROE (Latest)
-32.39%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -118.56 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-23What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -171.54 MM

ROCE(HY)

Lowest at -36.01%

DEBT-EQUITY RATIO (HY)

Highest at -53.64 %

OPERATING PROFIT(Q)

Lowest at USD -75.72 MM

PRE-TAX PROFIT(Q)

Lowest at USD -70.06 MM

NET PROFIT(Q)

Lowest at USD -70.06 MM

EPS(Q)

Lowest at USD -1.19

Here's what is working for Cullinan Therapeutics, Inc.
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Cullinan Therapeutics, Inc.
Pre-Tax Profit
At USD -70.06 MM has Fallen at -56.88%
over average net sales of the previous four periods of USD -44.65 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -70.06 MM has Fallen at -56.78%
over average net sales of the previous four periods of USD -44.68 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD -171.54 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit
Lowest at USD -75.72 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -70.06 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -70.06 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD -1.19
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debt-Equity Ratio
Highest at -53.64 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."